Follow-up of Osteo-articular Biomarkers After Spa Therapy at Dax in a Population With Knee Osteoarthritis and Their Correlation With the Clinical Evolution
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Knee Osteoarthritis
- Sponsor
- Ch Mont de Marsan
- Enrollment
- 37
- Locations
- 1
- Primary Endpoint
- Describe the change of serum level of Hyaluronic acid (a marker of synovial inflammation)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Spa therapy is used in the treatment of various diseases and mainly osteoarthritis. Knee osteoarthritis is a very common rheumatic disease whose prevalence increases with longer life span and is a public health problem.
The Forestier and al. study highlighted the actual benefit and confirmed the improvement of the quality of life and pain of the knee osteoarthritis patients from 6 months of spa treatment.[1] A significant decrease of 30% in the rate of Serum Hyaluronic Acid at 6 months after the end of the spa therapy was also highlighted in the Canteloup et al study.[6] This study aims to measure different osteoarticular biomarkers (hyaluronic acid, coll2-1 and CTX1) before, at the end of the spa therapy and 6 months after the spa therapy and correlate with the clinical evaluation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with knee osteoarthritis defined according to the recommendations of the American College of Rheumatology (ACR):
- •painful articulation and at least one of the following three criteria: age \> 50 years and/or articular crepitation and/or morning stiffness less than 30min
- •and radiographic sign of gonarthrosis with osteophyte (on X-rays of less than 3 years).
- •Patient can come to the final visit at 6 months and living within a perimeter of 30km around Dax.
- •Patient affiliated to a social security scheme.
Exclusion Criteria
- •Osteoarthritis limited to patellofemoral joint.
- •A previous spa therapy of less than 6 months.
- •Spa therapies with double indication rheumatology and phlebology.
- •Patient with osteoporosis.
- •A known hepatocellular failure or known acute or end-stage renal failure.
- •Severe depressive syndrome, psychotic syndrome, immune deficiency, cardiopathy, evolutive neoplasia or infection.
- •Infiltration and/or viscosupplementation \< 6 months.
- •Change in anti-osteoarthritis treatment of less than 3 months.
- •Patient under tutorship or curatorship.
Outcomes
Primary Outcomes
Describe the change of serum level of Hyaluronic acid (a marker of synovial inflammation)
Time Frame: 6 months (timepoint: at Day 0, Week 3 and month 6)
Measure of serum level of Hyaluronic acid before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
Secondary Outcomes
- Index of symptomatic severity of knee osteoarthritis or WOMAC(6 months (timepoint: at Day 0, Week 3 and month 6))
- Marker of cartilage degradation: Coll2-1(6 months (timepoint: at Day 0, Week 3 and month 6))
- Marker of bone resorption: CTX1(6 months (timepoint: at Day 0, Week 3 and month 6))
- Pain evaluation Visual Analogue Scale(6 months (timepoint: at Day 0, Week 3 and month 6))
- SF 36 Quality of Life Questionnaire(6 months (timepoint: at Day 0, Week 3 and month 6))
- Global clinical evaluation with kne flexion and joint swelling(6 months (timepoint: at Day 0, Week 3 and month 6))